Literature DB >> 28481873

Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma.

H Goto1, R Kariya1, E Kudo1, Y Okuno2, K Ueda3, H Katano4, S Okada1.   

Abstract

Primary effusion lymphoma (PEL), which is an aggressive subgroup of B-cell lymphoma associated with Kaposi sarcoma-associated herpes virus/human herpes virus-8, is refractory to the standard treatment, and exhibits a poor survival. Although PU.1 is downregulated in PEL, the potential role of its reduction remains to be elucidated. In this investigation, we analyzed the DNA methylation of PU.1 cis-regulatory elements in PEL and the effect of restoring PU.1 on PEL cells. The mRNA level of PU.1 was downregulated in PEL cells. The methylated promoter and enhancer regions of the PU.1 gene were detected in PEL cells. Suppression of cell growth and apoptosis were caused by the restoration of PU.1 in PEL cells. A microarray analysis revealed that interferon-stimulated genes (ISGs) including pro-apoptotic ISGs were strongly increased in BCBL-1 cells after the induction of PU.1. Reporter assays showed that PU.1 transactivated pro-apoptotic ISG promoters, such as the XAF1, OAS1 and TRAIL promoters. Mutations at the PU.1 binding sequences suppressed its transactivation. We confirmed the binding of PU.1 to the XAF1, OAS1 and TRAIL promoters in a chromatin immunoprecipitation assay. PU.1 suppressed ORF57 activation by inducing IRF7. The reinduction of PU.1 reduced formation of ascites and lymphoma cell infiltration of distant organs in PEL xenograft model mice. Collectively, PU.1 has a role in tumor suppression in PEL and its down-regulation is associated with PEL development. Restoring PU.1 with demethylation agents may be a novel therapeutic approach for PEL.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28481873     DOI: 10.1038/onc.2017.138

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

1.  Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

Authors:  R G Nador; E Cesarman; A Chadburn; D B Dawson; M Q Ansari; J Sald; D M Knowles
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

2.  Promoter- and cell-specific transcriptional transactivation by the Kaposi's sarcoma-associated herpesvirus ORF57/Mta protein.

Authors:  Diana Palmeri; Sophia Spadavecchia; Kyla Driscoll Carroll; David M Lukac
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

3.  Regulation of B lymphocyte and macrophage development by graded expression of PU.1.

Authors:  R P DeKoter; H Singh
Journal:  Science       Date:  2000-05-26       Impact factor: 47.728

4.  The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis.

Authors:  J C Castelli; B A Hassel; A Maran; J Paranjape; J A Hewitt; X L Li; Y T Hsu; R H Silverman; R J Youle
Journal:  Cell Death Differ       Date:  1998-04       Impact factor: 15.828

Review 5.  Molecular virology of Kaposi's sarcoma-associated herpesvirus.

Authors:  P S Moore; Y Chang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

6.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

7.  Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma.

Authors:  Hiroki Goto; Eriko Kudo; Ryusho Kariya; Manabu Taura; Harutaka Katano; Seiji Okada
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-11       Impact factor: 4.553

8.  Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.

Authors:  Hiro Tatetsu; Shikiko Ueno; Hiroyuki Hata; Yasuhiro Yamada; Motohiro Takeya; Hiroaki Mitsuya; Daniel G Tenen; Yutaka Okuno
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

9.  Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors.

Authors:  Stephen L Nutt; Donald Metcalf; Angela D'Amico; Matthew Polli; Li Wu
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

10.  INTERFEROME: the database of interferon regulated genes.

Authors:  Shamith A Samarajiwa; Sam Forster; Katie Auchettl; Paul J Hertzog
Journal:  Nucleic Acids Res       Date:  2008-11-07       Impact factor: 16.971

View more
  3 in total

1.  Overexpression of long non-coding RNA WT1-AS or silencing of PIK3AP1 are inhibitory to cervical cancer progression.

Authors:  Wenjuan Tong; Huiming Zhang
Journal:  Cell Cycle       Date:  2021-11-28       Impact factor: 4.534

2.  Down-regulation and clinical significance of miR-7-2-3p in papillary thyroid carcinoma with multiple detecting methods.

Authors:  Hua-Yu Wu; Yi Wei; Shang-Ling Pan
Journal:  IET Syst Biol       Date:  2019-10       Impact factor: 1.615

3.  Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.

Authors:  Mark Manzano; Thomas Günther; Hyunwoo Ju; John Nicholas; Elizabeth T Bartom; Adam Grundhoff; Eva Gottwein
Journal:  mBio       Date:  2020-08-25       Impact factor: 7.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.